.
MergerLinks Header Logo

Announced

Keensight Capital to acquire 3P Biopharmaceuticals from Infraco.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

pharmaceutical company

Pharmaceuticals

Private Equity

Spain

Acquisition

Private

Single Bidder

Friendly

Majority

Pending

Synopsis

Edit

Private equity firm Keensight Capital is set to acquire 3P Biopharmaceuticalss, a leading Contract Development and Manufacturing Organization in Spain, from Infraco. Financial terms were not disclosed. “This is an exciting new chapter for 3P Biopharmaceuticals, we are extremely enthusiastic to work hand in hand with Keensight Capital at such a crucial moment for our industry. With their global footprint and their expertise in the biologics field, I am highly confident that the Keensight team will help us reach significant milestones in the coming years,” Dámaso Molero, 3P Biopharmaceuticals General Manager.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US